CD274 and neoplasm: Therapy with this strategy alone using PD-L1 blocking antibodies showed a mixed response within the patient populations leading to the development of vaccines and T cell stimulatory molecules, or drug combinations along with PD-L1 inhibitors to improve the efficacy of immunotherapy by targeting more pathways that lead to tumor cell death and growth suppression (159–165).